MichaelDavidBanovMDDFAPA,CPI
Psychiatry • Marietta, GAMedical Director of PsychAtlanta, PsychAtlanta Ketamine, and PsychAtlanta Research
Dr. Banov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1012 Coggins Place
Marietta, GA 30060Phone+1 770-422-2009Fax+1 770-428-0330- Is this information wrong?
Summary
- Dr. Michael Banov is a Psychiatrist in Marietta and Alpharetta GA. He received his medical degree from Emory University School of Medicine and has been in practice 28 years. He specializes in treatment resistant depression and other refractory psychiatric conditions utilizing novel pharmacological therapies including ketamine, Spravato, and TMS. He has been conducting clinical trials for over 25 years and has published extensively on new treatments for psychiatric conditions.
Education & Training
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1990 - 1993
Boston University Medical CenterInternship, Internal Medicine, 1989 - 1990
Emory University School of MedicineClass of 1989
Certifications & Licensure
GA State Medical License 1994 - 2025- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification RcopiaMU EHR, DrFirst.com, Inc., 2013
Clinical Trials
- Treatment-Resistant Depression Registry Start of enrollment: 2006 Jan 01
- Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2014 Oct 01
- Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Publications & Presentations
PubMed
- Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controll...Calabrese JR, Frye MA, Yang R, Ketter TA, Armodafinil Treatment Trial Study Network> ;The Journal of clinical psychiatry.
- 12 citationsThe Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind,...Stanley E. Althof, Ian H. Osterloh, Gary J. Muirhead, Katie George, Nicolas Girard, W. Jennings, Michael A. Adams, S. Althof, G. Shockey, Jed Kaminetsky, Martin Miner,...> ;The Journal of Sexual Medicine. 2019 Aug 1
- 2 citationsSwitching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.Michael D Banov, Rachel E Landrum, Michelle B. Moore, Steven T. Szabo> ;Journal of Clinical Psychopharmacology. 2021 Aug 13
- Join now to see all
Press Mentions
Is Ketamine a Safe at-Home Treatment for Depression?May 12th, 2023- Ketamine Has Become an at-Home Treatment for Depression, but Some Scientists Say That Set-up Is Too RiskyFebruary 23rd, 2023
- Industry Briefs November 2022November 22nd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
